Trials / Unknown
UnknownNCT05682612
Prognostic Value of PtcO2 in Patients With COVID-19
Prognostic Value of Transcutaneous Partial Pressure of Oxygen in Patients With Novel Coronavirus Infection
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Southeast University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Detailed description
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | outcome | hospital survivors and nonsurvivors |
| OTHER | Subtype of COVID-19 | Different subtype of COVID-19 |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2023-12-01
- Completion
- 2023-12-30
- First posted
- 2023-01-12
- Last updated
- 2023-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05682612. Inclusion in this directory is not an endorsement.